AU2020226422C1 - Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof - Google Patents

Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof

Info

Publication number
AU2020226422C1
AU2020226422C1 AU2020226422A AU2020226422A AU2020226422C1 AU 2020226422 C1 AU2020226422 C1 AU 2020226422C1 AU 2020226422 A AU2020226422 A AU 2020226422A AU 2020226422 A AU2020226422 A AU 2020226422A AU 2020226422 C1 AU2020226422 C1 AU 2020226422C1
Authority
AU
Australia
Prior art keywords
alkyl
alkoxy
compound
membered
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020226422A
Other languages
English (en)
Other versions
AU2020226422B2 (en
AU2020226422A1 (en
Inventor
Zhonghui CHEN
Shuangshuang DUAN
Runfeng HAN
Xiaojun Han
Liandong JING
Guiying Li
Hongmei SONG
Qizheng SUN
Qiang Tian
Jingyi Wang
Tongtong XUE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Original Assignee
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Publication of AU2020226422A1 publication Critical patent/AU2020226422A1/en
Application granted granted Critical
Publication of AU2020226422B2 publication Critical patent/AU2020226422B2/en
Publication of AU2020226422C1 publication Critical patent/AU2020226422C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2020226422A 2019-02-19 2020-02-11 Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof Active AU2020226422C1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN201910124584.6 2019-02-19
CN201910124584 2019-02-19
CN201910437878 2019-05-24
CN201910437878.4 2019-05-24
CN201910932095.3 2019-09-29
CN201910932095 2019-09-29
PCT/CN2020/074696 WO2020168939A1 (zh) 2019-02-19 2020-02-11 杂环化合物、包含其的药物组合物及其制备方法和用途

Publications (3)

Publication Number Publication Date
AU2020226422A1 AU2020226422A1 (en) 2021-09-09
AU2020226422B2 AU2020226422B2 (en) 2025-07-31
AU2020226422C1 true AU2020226422C1 (en) 2026-04-02

Family

ID=72143544

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020226422A Active AU2020226422C1 (en) 2019-02-19 2020-02-11 Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof

Country Status (16)

Country Link
US (1) US20220144847A1 (https=)
EP (1) EP3929198A4 (https=)
JP (2) JP7615056B2 (https=)
KR (1) KR20210131314A (https=)
CN (3) CN117263945A (https=)
AU (1) AU2020226422C1 (https=)
BR (1) BR112021016299A2 (https=)
CA (1) CA3130245A1 (https=)
CL (1) CL2021002205A1 (https=)
CO (1) CO2021011023A2 (https=)
IL (1) IL285378B2 (https=)
MX (1) MX2021009971A (https=)
PH (1) PH12021552004A1 (https=)
SA (1) SA521430084B1 (https=)
SG (1) SG11202107848TA (https=)
WO (1) WO2020168939A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022022398A1 (zh) * 2020-07-28 2022-02-03 四川科伦博泰生物医药股份有限公司 一种嘧啶类化合物的盐和晶型及其制备方法
KR20230159367A (ko) * 2021-03-24 2023-11-21 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 키나아제 약물 내성 돌연변이와 관련된 질병의 치료에있어서의 헤테로사이클릭 화합물의 용도 및 그 방법
CN114235976B (zh) * 2021-11-09 2023-11-03 暨南大学 一种含氮杂环有机化合物中间产物的合成和分析方法
CN120897743A (zh) 2023-05-19 2025-11-04 四川科伦博泰生物医药股份有限公司 杂环化合物治疗与ret基因改变相关疾病的用途和方法
WO2025256440A1 (zh) * 2024-06-14 2025-12-18 四川科伦博泰生物医药股份有限公司 含杂环化合物富马酸盐的制备方法
WO2026017002A1 (zh) * 2024-07-16 2026-01-22 四川科伦博泰生物医药股份有限公司 以杂环化合物为活性成分的药物组合物、其制备方法及用途
GB202410599D0 (en) 2024-07-19 2024-09-04 Ellipses Pharma Ltd Therapeutics useful synergistic combinations

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101166734A (zh) * 2005-02-28 2008-04-23 日本烟草产业株式会社 具有Syk抑制活性的新型的氨基吡啶化合物
WO2008146914A1 (ja) * 2007-06-01 2008-12-04 Mitsubishi Tanabe Pharma Corporation 複素環化合物
WO2011115183A1 (ja) * 2010-03-17 2011-09-22 大日本住友製薬株式会社 新規単環ピリミジン誘導体
WO2012154518A1 (en) * 2011-05-10 2012-11-15 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as syk inhibitors
CN103298788A (zh) * 2010-10-28 2013-09-11 日本新药株式会社 吡啶衍生物及医药

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0607062A2 (pt) 2005-02-28 2009-08-04 Japan Tobacco Inc composto de aminopiridina com atividade inibidora de syk, composição farmacêutica e agente terapêutico compreendendo os mesmos
WO2008013622A2 (en) * 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
US20080234267A1 (en) * 2007-03-20 2008-09-25 Karen Elizabeth Lackey Compounds and Methods of Treatment
ES2539170T3 (es) 2010-01-12 2015-06-26 Ab Science Inhibidores de quinasas de oxazol
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
SI3371171T1 (sl) 2015-11-02 2024-03-29 Blueprint Medicines Corporation Inhibitorji ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101166734A (zh) * 2005-02-28 2008-04-23 日本烟草产业株式会社 具有Syk抑制活性的新型的氨基吡啶化合物
WO2008146914A1 (ja) * 2007-06-01 2008-12-04 Mitsubishi Tanabe Pharma Corporation 複素環化合物
WO2011115183A1 (ja) * 2010-03-17 2011-09-22 大日本住友製薬株式会社 新規単環ピリミジン誘導体
CN103298788A (zh) * 2010-10-28 2013-09-11 日本新药株式会社 吡啶衍生物及医药
WO2012154518A1 (en) * 2011-05-10 2012-11-15 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as syk inhibitors

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CAS Registry Number 1349069-14-2; STN Entry Date 5 December 2011; N-[6-[2-(4-Methoxy-1-piperazinyl)-5-thiazolyl]-2-pyridinyl]-4-methyl-2-pyridinamine *
CAS Registry Number 1349252-44-3; STN Entry Date 5 December 2011; 4-[5-[6-[(4-Methyl-2-pyridinyl)amino]-2-pyridinyl]-2-thiazolyl]-N-[2-(4-morpholinyl)ethyl]-1-piperidinecarboxamide *
CAS Registry Number 1374201-58-7; STN Entry Date: 22 May 2012; 4-[6-[(4-Cyano-2-pyridinyl)amino]-4-cyclopropyl[2,3'-bipyridin]-6'-yl]-1-piperazineacetic acid *
CAS Registry Number 909343-99-3; STN Entry Date: 2 October 2006; N-(2-Methoxyethyl)-N-methyl-1-[5-[6-[(4-methyl-2-pyridinyl)amino]-2-pyridinyl]-2-thiazolyl]-4-piperidinecarboxamide *
CAS Registry Number 909344-03-2; STN Entry Date 2 October 2006; 1-[5-[6-[(4,6-Dimethyl-2-pyridinyl)amino]-2-pyridinyl]-2-thiazolyl]-4-piperidineacetic acid *
CAS Registry Number: 909344-08-7; STN Entry Date 2 October 2006; 1-[5-[6-(2-Pyridinylamino)-2-pyridinyl]-2-thiazolyl]-4-piperidinecarboxylic acid *
DATABASE REGISTRY CAS Registry Number 909344-04-3; STN Entry Date 2 October 2006; 1-[5-[6-[(6-Methyl-2-pyridinyl)amino]-2-pyridinyl]-2-thiazolyl]-4-piperidineacetic acid *
LI, BINGKE ET AL, COMPUTERS IN BIOLOGY AND MEDICINE, vol. 43, no. 4, 1 May 2013, pp 395-404 *
WATANABE MANABU ET AL: "Dihydropyrrolo[2,3- d ]pyrimidines: Selective Toll-Like Receptor 9 Antagonists from Scaffold Morphing Efforts", ACS MEDICINAL CHEMISTRY LETTERS, vol. 5, no. 11, 6 October 2014 (2014-10-06), US, pages 1235 - 1239, *

Also Published As

Publication number Publication date
NZ778907A (en) 2025-05-30
JP2025060928A (ja) 2025-04-10
IL285378B2 (en) 2025-11-01
PH12021552004A1 (en) 2022-09-05
US20220144847A1 (en) 2022-05-12
CO2021011023A2 (es) 2021-09-09
CN113316578A (zh) 2021-08-27
CN113316578B (zh) 2023-10-31
WO2020168939A1 (zh) 2020-08-27
AU2020226422B2 (en) 2025-07-31
IL285378A (en) 2021-09-30
IL285378B1 (en) 2025-07-01
JP2022521859A (ja) 2022-04-12
EP3929198A4 (en) 2022-11-16
JP7821259B2 (ja) 2026-02-26
CN117263945A (zh) 2023-12-22
CA3130245A1 (en) 2020-08-27
CL2021002205A1 (es) 2022-04-22
JP7615056B2 (ja) 2025-01-16
SG11202107848TA (en) 2021-08-30
MX2021009971A (es) 2021-10-13
AU2020226422A1 (en) 2021-09-09
BR112021016299A2 (pt) 2021-10-13
EP3929198A1 (en) 2021-12-29
KR20210131314A (ko) 2021-11-02
SA521430084B1 (ar) 2025-05-01
CN117327078A (zh) 2024-01-02

Similar Documents

Publication Publication Date Title
AU2020226422C1 (en) Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof
JP7017521B2 (ja) アクチビン受容体様キナーゼの阻害剤
AU2023207390A1 (en) Six-membered cyclothiazole compound and use thereof
KR101921486B1 (ko) ＰＡＲＰ억제제인 4Ｈ-피라졸로[1,5-ａ]벤즈이미다졸 화합물의 아날로그
JP2022525749A (ja) Ｊａｋキナーゼ阻害剤及びその調製方法、並びにその医薬分野での使用
EP3784671B1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
EP3753941A1 (en) Pyrimidine-fused cyclic compound, preparation method therefor and application thereof
TW202130631A (zh) ３—（５—甲氧基—１—側氧基異吲哚啉—２—基）哌啶—２，６—二酮衍生物及其用途
CN111484479B (zh) 氮杂环化合物、包含其的药物组合物及其制备方法和用途
BR112021011147A2 (pt) Benzamidas de derivados de pirazolil-amino-pirimidinila e composições e métodos das mesmas
TW202237597A (zh) 新型egfr降解劑
EP3936509B1 (en) Fgfr4 kinase inhibitor, preparation method therefor and use thereof
US20250268897A1 (en) Use of heterocyclic compound in treating diseases related to kinase drug-resistant mutation and method therefor
TW202400580A (zh) 作為配體導向降解劑之bcl6調節劑
CN115340559A (zh) Shp2磷酸酶杂环类抑制剂的制备及其应用
CN110818704A (zh) 螺桥环化合物、其药物组合物及其用途
US20240092761A1 (en) Quinazoline compounds and methods of use
CN112574201B (zh) 芳基胺类化合物、包含其的药物组合物及其制备方法和用途
WO2023139536A1 (en) (4-piperazin-1yl)-4-alkyl-phthalazin-1(2h)-one compounds as parp7 inhibitors
RU2828045C2 (ru) Гетероциклическое соединение, фармацевтическая композиция, содержащая его, способ его получения и его применение
CN117003756B (zh) 芳香稠环化合物作为trek-1激活剂的用途、包含其的药物组合物、镇痛剂
HK40051009A (en) Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof
CN117659022A (zh) 脲基取代吡啶类化合物、包含其的药物组合物及其医药用途
TW202521109A (zh) 氮聯結苯并異㗁唑磺醯胺衍生物
HK40051009B (zh) 杂环化合物、包含其的药物组合物及其制备方法和用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 09 DEC 2025

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 09 DEC 2025